|
|
Do your patients always get the product that you intended them to get?
The answer is simple: no. During this period of transition from CFC products to HFA products, there has been some uncertainty regarding the availability of generic albuterol HFA MDIs. To clear up matters, the fact is there are NO generic albuterol HFA MDIs. Therefore, once the transition period has expired and the CFC products are no longer sold or produced, you will need to choose from the available branded HFA MDI products or other medications for your patients.
You can take matters into your own hands:
If you want your patients to have all of the benefits of XOPENEX HFA, then you must specifically indicate the brand name on the prescription:
1 to 2 puffs every 4 to 6 hours1
Approved for the treatment or prevention of bronchospasm in adults, adolescents, and children, 4 years of age and older with reversible obstructive airway disease.1
|
 |
|
©2007 Sepracor Inc. All rights reserved |
 |
Important Safety Information
XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any component of XOPENEX HFA. XOPENEX HFA and other β-agonists can produce paradoxical bronchospasm, which may be life threatening. If additional adrenergic drugs, including other short-acting sympathomimetic bronchodilators or epinephrine, are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Due to the cardiovascular side effects associated with β-agonists, caution is generally recommended for patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), diabetes, hyperthyroidism, or convulsive disorders. Do not exceed the recommended dose. Fatalities have been reported in association with excessive use of sympathomimetic drugs in patients with asthma. Please refer to the full prescribing information regarding potential drug interactions with β-blockers, diuretics, digoxin, or MAOI and tricyclic antidepressants.
XOPENEX HFA Inhalation Aerosol
In patients aged 4 to 11 years, the most common adverse events (occurring in ≥2% of patients receiving XOPENEX HFA at 90 mcg and more frequently than patients receiving placebo) were vomiting, accidental injury, pharyngitis, and bronchitis.
In patients 12 years and older, the most common adverse events (occurring in ≥2% of patients receiving XOPENEX HFA at 90 mcg and more frequently than patients receiving placebo) were asthma, pharyngitis, rhinitis, pain, and dizziness.
